Tag Archives: Repurposing of Drugs

Medicine to Ease Enlarged Prostate Re-Purposed for Parkinson’s Disease? (BBC News / Journal of Clinical Investigation)

Posted on September 20, 2019 by Dementia and Elderly Care News

Summary Terazosin, a drug developed originally to treat benign prostatic hyperplasia (BPH), may slow the progression of Parkinson’s Disease. It is thought that Terazosin may help by activating an enzyme (PGK1) which prevents cell death in the relevant brain regions. … Continue reading →

Posted in BBC News, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Parkinson's Disease, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged BBC Health News, Beijing Institute for Brain Disorders: Capital Medical University, Benign Prostatic Hyperplasia (BPH), Capital Medical University (Beijing), Center of Stroke: Beijing Institute for Brain Disorders, China, Disease-Modifying Treatments for Parkinson's Disease, Drugs Development and Re-Purposing, Institute of Hypoxia Medicine: Xuanwu Hospital, Journal of Clinical Investigation, Key Laboratory for Neurodegenerative Diseases of the Ministry of Education (China), Off-Label Drug Repurposing Trials, PGK1, Potential Repurposing of Drugs to Slow Progression of Parkinson’s Disease, Repurposing of Drugs, Terazosin, Xuanwu Hospital (China) | Leave a comment

Animal Study Explores the Potential of a Novel Diabetes Drug for Reducing Memory Loss in Dementia – In Mice (NHS Choices / Brain Research)

Posted on January 13, 2018 by Dementia and Elderly Care News

Summary Early animal research indicates that a new drug designed for the future treatment of diabetes may (one day) have an alternative re-use for reducing the memory-loss symptoms of Alzheimer’s Disease. Mice given a modified version of a so-called triple … Continue reading →

Posted in Alzheimer's Society, Animal Studies, Charitable Bodies, For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Alzheimer's Society, Alzheimer’s Disease and Diabetes, Amyloid Plaque Load, APP/PS1 Transgenic Mouse Model, Bazian, BDNF Levels in Hippocampus of APP/PS1 Mice, BDNF: Brain-Derived Neurotrophic Factor, Behind the Headlines, Biomedical and Life Science: Lancaster University, Brain Research, Brain Research (Journal), Brain-Derived Neurotrophic Factor (BDNF), China, Critical Appraisals, Department of Human Anatomy: Shaoyang University, Diabetes Drugs, Faculty of Health and Medicine: Lancaster University, GIP Receptor Agonists, GLP-1/GIP Dual Agonists, Glucagon-Like Peptide-1 (GLP-1) Analogs, Incretin Hormones, Incretin Mimetics, Inflammation, β-Amyloid Plaques, Key Laboratory of Cellular Physiology: Shanxi Medical University, Lancaster University, Medical College: Shaoyang University, Memory Loss, Ministry of Human Resources and Social Security (Shanxi Scholarship Council of China), Morris Water Maze Test, Mouse Model of Alzheimer’s Disease, Mouse Models of Alzheimer's Disease, Neuroprotection, Neuroprotection Research, Neuroprotective Agents, Neuroprotective Effects of Triple GLP-1/GIP/Glucagon Receptor Agonist, Novel GLP-1/GIP/Gcg Receptor Agonist, Off-Label Drug Repurposing Trials, Oxidative Stress, People's Republic of China, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Repurposing GLP-1 Agonists, Repurposing of Drugs, Second Hospital Neurology Department: Shanxi Medical University, Shanxi Medical University, Shanxi Medical University (China), Shanxi Scholarship Council of China, Shaoyang University, Shaoyang University (China), Synaptophysin (SYN) Levels, Transgenic Mice, Triple GLP-1/GIP/Glucagon Receptor Agonist, Triple GLP-1/GIP/Glucagon Receptor Agonists, Triple Receptor Agonist (TA) Drugs, Type 2 Diabetes, Type 2 Diabetes Drugs Development and Re-Purposing, Type 2 Diabetes Mellitus (T2DM), Water Maze Test | Leave a comment

Parkinson’s Disease in Adults: Updated Guidance (NICE / BBC News / NHS Choices / Lancet)

Posted on August 4, 2017 by Dementia and Elderly Care News

Summary The National Institute for Health and Care Excellence recently released an updated guideline on the diagnosis and management of Parkinson’s Disease in patients aged over 18 years. This guidance updates and replaces their earlier “NG35 – Parkinson’s disease in … Continue reading →

Posted in BBC News, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, National, NHS Digital (Previously NHS Choices), NICE Guidelines, Non-Pharmacological Treatments, Parkinson's Disease, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, UK | Tagged : National Institute on Aging (USA), Amantadine, BBC Health News, Behind the Headlines, Biomedical Research Centres (NIHR), Comprehensive Clinical Trials Unit: University College London, COMT Inhibitors, Deep Brain Stimulation (DBS), Diagnosing Parkinson's Disease, Dopamine Agonists, Dr Brian Fiske: The Michael J Fox Foundation for Parkinson's Research, Exenatide, Exenatide as Potential Treatment for Patients with Parkinson's Disease, GLP-1 Agonists for Parkinson's Disease, Impulse Control Disorders, Impulse Control Disorders (ICDs), Impulsive-Compulsive Disorders, Impulsivity, Information and Support, Institute of Nuclear Medicine: University College London Hospitals NHS Trust, Intramural Research Program: National Institute on Aging, Leonard Wolfson Experimental Neuroscience Centre, Levodopa, Levodopa–Carbidopa Intestinal Gel, MAO‑B Inhibitors, Michael J Fox Foundation, Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), National Hospital for Neurology and Neurosurgery, National Hospital for Neurology and Neurosurgery: UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery: University College London Hospitals NHS Foundation Trust, National Institute for Health and Care Excellence (NICE), National Institute for Health Research Biomedical Research Centres, National Institute for Health Research UCL Hospitals Biomedical Research Centre, National Institutes of Health (Baltimore), Neurological Disease, Neurological Disorders, NHNN: National Hospital for Neurology and Neurosurgery, NIHR Biomedical Research Centres, Non-Pharmacological Management of Symptoms, Occupational Therapy, Off-Label Drug Repurposing Trials, Palliative Care, Parkinson's, Parkinson's Disease in Over 20s (Updated and Replaced), Parkinson’s Disease, Parkinson’s Disease Diagnosis, Parkinson’s Disease In Adults: NICE Guidance (NG71), Parkinson’s Disease in Adults: Updated Guidance (NICE 2017), Parkinson’s Pathway, Parkinsonian Symptoms, Pharmacological Management of Motor Symptoms, Pharmacological Management of Non-Motor Symptoms, Potential Repurposing of Drugs to Slow Progression of Parkinson’s Disease, Professor David Dexter: Parkinson's UK, Repurposing GLP-1 Agonists, Repurposing of Drugs, Sobell Department of Motor Neuroscience (UCL), Speech and Language Therapy (SALT), Translational Gerontology Branch: National Institute on Aging, Type 2 Diabetes Drug: Exenatide, University College London (UCL), University College London Hospitals NHS Trust, University College London Institute of Neurology, University College London Institute of Neurology and the National Hospital for Neurology and Neurosurgery, US National Institute of Aging | Leave a comment

Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)

Posted on April 20, 2017 by Dementia and Elderly Care News

Summary Animal research, involving mice, has indicated promising results for the potential of two re-purposed drugs in helping to slow or halt the progression of a number of neurodegenerative brain diseases, including dementia. “The best known drug of the pair … Continue reading →

Posted in Animal Studies, BBC News, For Researchers (mostly), In the News, National, NHS Digital (Previously NHS Choices), Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Abnormal Prion Protein, Alzheimer's Disease, Alzheimer's Research UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Autoimmune Attacks, Autoimmune Cell Defences, BBC Health News, Behind the Headlines, Brain (Journal), Centre for Analytical Bioscience: University of Nottingham, CJD, Creutzfeldt-Jakob Disease, Creuzfeldt Jacob Disease (CJD), Department of Clinical Neurosciences: University of Cambridge, Dibenzoylmethane, Dibenzoylmethane (DBM): Potential Anti-Cancer Drug, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr David Dexter: Parkinson's UK, Dr Doug Brown: Director of Research and Development at Alzheimer's Society, Drug Discovery Programmes, eIF2a-P-Mediated Translational Repression (Pathway of Neurodegeneration), Frontotemporal Dementia (FTD), Huntingtin Protein, Huntington’s Disease, α-Synuclein, α-Synuclein Aggregation, Lentivirally Mediated RNA Interference (RNAi), Medical Research Council (MRC), Medical Research Council (UK), Medical Research Council Toxicology Unit: University of Leicester, Medical Research Council’s (MRC) Toxicology Unit, Microscopic Worms, Misfolded Prion Protein (PrP), Misfolded Proteins, Motor Neurone Disease (MND), MRC Toxicology Unit: University of Leicester, MRC: Medical Research Council, Multiple Sclerosis, National Institute for Neurological Disorders and Stroke, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuronal Loss, Neuroprotection, Parkinson's, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prion Diseases, Prion Protein (PrP(C)), Prion-Infected Mice, Prof. Giovanna Mallucci, Professor Giovanna Mallucci: Associate Drector of UK Dementia Research Institute, Protein Misfolding, Rare Prion Diseases, Repurposing of Drugs, Synucleinopathy, Tau, Tau Protein, Tauopathy, Translational Research, Transmissible Spongiform Encephalopathies, Trazodone, Trazodone Hydrochloride (Antidepressant), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Unfolded Protein Response (UPR), University of Cambridge, University of Leicester, University of Nottingham, Worms: C. elegans | Leave a comment

Repurposing of Existing Drugs to Prevent Dementia? (BBC News / Science Advances /Alzheimer’s Research UK)

Posted on February 13, 2016 by Dementia and Elderly Care News

Summary A number of drugs, already approved as safe for the treatment of other conditions, and which could help protect against Alzheimer’s Disease, are said to have been detected and short-listed for further investigation. Full Text Link Reference Alzheimer’s preventative … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Animal Studies, BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Ab42 Fibril Formation, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta Protein, Amyloid Cascade Hypothesis, Amyloid Hypothesis, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β Protein, Anti-Amyloid Therapies, ARUK: Alzheimer’s Research UK, ß-amyloid, BBC Health News, Behind the Headlines, Beta-Amyloid, Bexarotene (Elevated Triglycerides), Bexarotene (Targretin), Center for Molecular Protein Science: Lund University, Cleveland Clinic Lou Ruvo Center for Brain Health, Collaborative Drug Discovery Programmes, Conversion to Dementia From Prodromal Disease, Critical Appraisals, Department of Biochemistry and Structural Biology: Lund University, Department of Chemistry: University of Cambridge, Department of Psychology: University of Nevada, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, European Research Institute for the Biology of Aging (Groningen), Fibrillar Deposits (Alzheimer's Disease), Fibrils, β-Amyloid 1-42 (Aβ42), Lund University (Sweden), Microscopic Worms, Netherlands, Neurofibrillary Tangles (NFTs), Neurological Research, Neurostatin (Hypothetical Construct), Off-Label Drug Repurposing Trials, Off-Licence Drugs, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prodromal Alzheimer's Disease, Protein Aggregation, Repurposing of Drugs, RXR Agonists, Science Advances (Journal), Statins for the Brain (Hypothetical Construct), Sweden, University Medical Centre Groningen, University of Cambridge, University of Groningen, University of Nevada, USA, Worms: C. elegans | Leave a comment

Brief Introduction to the DIAN-TU Study (BBC News)

Posted on October 23, 2015 by Dementia and Elderly Care News

Summary The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is based at University College Hospital in London, and has the aim of finding ways to prevent the development of Alzheimer’s Disease in people at high risk, before physical / clinical … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Alzheimer’s Disease Biomarkers, BBC Health News, Biomarkers, Conversion Rates, Conversion to Dementia, Conversion to Dementia From Prodromal Disease, Dementia Research, DIAN-TU Study, DIAN-TU Trial, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Early-Onset Alzheimer's Gene, Early-Onset Dementia, Immunotherapy Drugs, MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), Neurological Research, Off-Label Drug Repurposing Trials, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Pre-Dementia (MCI), Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Prodromal Alzheimer's Disease, Rates of Conversion From Mild Cognitive Impairment to Dementia, Repurposing of Drugs, University College Hospital, University College Hospitals NHS Foundation Trust | Leave a comment

Cancer Drugs to Assist Nerve Regeneration? (BBC News / Brain)

Posted on May 31, 2015 by Dementia and Elderly Care News

Summary Researchers at Imperial College London have suggested that cancer drugs called nutlins may influence mechanisms with the potential for enabling certain aspects of CNS nerve regeneration (at least in animal studies involving severed spinal cords): Full Text Link Reference … Continue reading →

Posted in Animal Studies, BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, UK | Tagged Axonal Re-Growth and Functional Recovery, Axonal Regeneration, BBC Health News, Belgium, Brain: a Journal of Neurology, Centre for Neurology: University of Tuebingen, Centre of Experimental Orthopaedics: Saarland University Medical Centre, Department of Medicine: Imperial College London, Department of Molecular and Developmental Genetics: VIB-K.U.Leuven, Division of Brain Sciences: Imperial College London, Functional Recovery After CNS Injury, German Centre for Neurodegenerative Diseases (DZNE): Germany, Germany, Graduate School for Cellular and Molecular Neuroscience: University of Tuebingen, Hertie Institute for Clinical Brain Research: University of Tuebingen, Imperial College London, Laboratory for Molecular Cancer Biology: VIB-K.U.Leuven, Laboratory for NeuroRegeneration and Repair: University of Tuebingen, MDM4/MDM2-p53-IGF1 Axis, Molecular Neuroregeneration: Imperial College London, Neurological Research, Neuroplasticity, Nutlins, Off-Label Drug Repurposing Trials, Recovery After Central Nervous System Injury, Regeneration of Injured Central Nervous System Axons, Regenerative Medicine, Repurposing of Drugs, Saarland University Medical Centre, Spinal Cord Injury, Triad: the Ubiquitin Ligases MDM4 MDM2 and Transcription Factor p53 (Encoded by TP53), Tuebingen, University of Tuebingen, VIB Center for the Biology of Disease K.U.Leuven (VIB-K.U.Leuven), VIB-K.U.Leuven | Leave a comment

Tag Archives: Repurposing of Drugs

Medicine to Ease Enlarged Prostate Re-Purposed for Parkinson’s Disease? (BBC News / Journal of Clinical Investigation)

Parkinson’s Disease in Adults: Updated Guidance (NICE / BBC News / NHS Choices / Lancet)

Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)

Repurposing of Existing Drugs to Prevent Dementia? (BBC News / Science Advances /Alzheimer’s Research UK)

Brief Introduction to the DIAN-TU Study (BBC News)

Cancer Drugs to Assist Nerve Regeneration? (BBC News / Brain)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites